[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343530-105":59,"doc-detail-343530-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","blood-endocan-as-a-biomarker-for-breast-cancer-recurrence","Blood endocan as a biomarker for breast cancer recurrence","","Background: Endocan is reported to negatively affect breast cancer patients and can be detected in patients’ blood. Objective: Determine whether measuring blood endocan in breast cancer patients with high ESM1 expression can effectively identify postoperative recurrence compared with existing tumor markers. Methods: Blood endocan levels were measured in mouse models using noninvasive luminescence imaging, and in 16 clinical patients before and after tumor resection; 20 postoperative-recurrence patients were further tested.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/blood-endocan-as-a-biomarker-for-breast-cancer-recurrence/343530/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/blood-endocan-as-a-biomarker-for-breast-cancer-recurrence/343530.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of measuring blood endocan in this study?","Question",{"text":112,"@type":113},"To assess whether blood endocan measurement can detect postoperative recurrence in breast cancer patients with high ESM1 expression, compared with existing tumor markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were endocan levels evaluated in preclinical and clinical settings?",{"text":117,"@type":113},"Mouse models provided blood before and after tumor resection with metastatic recurrence visualized by noninvasive luminescence imaging, and clinical samples were taken from patients before and after resection.",{"name":119,"@type":110,"acceptedAnswer":120},"What key result supports the clinical relevance of endocan?",{"text":121,"@type":113},"Blood endocan levels reflected tumor burden, and over 60% of patients with postoperative recurrence who were negative for CEA or CA15-3 tested positive for endocan.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343530,1790552678,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Biomarkers 41 (2024) 145–154 145  \nDOI 10.3233/CBM-240034 IOS Press  \nBlood endocan as a biomarker for breast cancer recurrence  \nKentaro Daikia , Yoko Kanadab , Aya Nagatac , Kanae Tarunod , Katsuhide Igarashie , Toshiko Yamochif , Hirotaka Otaf , Fumiaki Satoa , Seigo Nakamurad ;􀀃 and Yoshinori Katoa ;􀀃  \na Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan  \nb Department of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan  \nc Department of Breast Surgical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan d Institute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan  \ne Laboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan  \nf Department of Pathology, Showa University School of Medicine, Tokyo, Japan  \nReceived 18 January 2024 Accepted 31 July 2024  \nAbstract.  \nBACKGROUND: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients'blood.  \nOBJECTIVE: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers.  \nMETHODS: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3) .  \nRESULTS: Our preclinical and clinical experiments revealed that blood endocan levels reﬂected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan. CONCLUSIONS: Our results support the clinical signiﬁcance of endocan in breast cancer patients for detecting breast cancer recurrence.  \nKeywords: Endocan, recurrence, biomarker, animal models, clinical study  \n1. Introduction  \nBreast cancer is now the leading cause of cancer incidence in women worldwide, accounting for one in  \n􀀃 Corresponding authors: Seigo Nakamura, Department of Surgery, Division of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan. Tel.: +81 3 3784 8707; E-mail: seigonak@ [med.showa-u.ac.jp. Yoshinori Kato](med.showa-u.ac.jp. Yoshinori Kato), Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan. Tel.: +81 3 5498 5844; E-mail: [y-kato@hoshi.ac.jp](y-kato@hoshi.ac.jp).  \nfour cancer cases and one in six cancer deaths [1] . Although the overall prognosis for breast cancer patients is relatively good when detected early, relative to other cancers, it has a high recurrence rate after surgery [2] . Cancer recurrence affects the patient's prognosis and quality of life, posing a critical clinical problem in later years as they often resist chemotherapy. The potential for recurrence and metastasis of breast cancer varies by subtypes, proliferative potential, and dormancy [3, 4] . Even in the same subtype, recurrence-free survival varies from patient to patient; some patients experience  \nISSN 1574-0153 􀀍c 2024 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4 .0) .  \n146 K. Daiki et al. / Endocan and breast cancer recurrence  \nrecurrence within one year, while others do not see any recurrence over ﬁve years. Therefore, it is beneﬁci","cbCaisr1RVZVz9t6","https://ap.wps.com/l/cbCaisr1RVZVz9t6","pdf",1927197,"English","# Abstract\n## Background, Objective, Methods, Results, Conclusions\n# 1. Introduction","[{\"question\":\"What is the main purpose of measuring blood endocan in this study?\",\"answer\":\"To assess whether blood endocan measurement can detect postoperative recurrence in breast cancer patients with high ESM1 expression, compared with existing tumor markers.\"},{\"question\":\"How were endocan levels evaluated in preclinical and clinical settings?\",\"answer\":\"Mouse models provided blood before and after tumor resection with metastatic recurrence visualized by noninvasive luminescence imaging, and clinical samples were taken from patients before and after resection.\"},{\"question\":\"What key result supports the clinical relevance of endocan?\",\"answer\":\"Blood endocan levels reflected tumor burden, and over 60% of patients with postoperative recurrence who were negative for CEA or CA15-3 tested positive for endocan.\"}]","Blood endocan as a biomarker for breast cancer recurrence | PDF",1790051393,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6038fd65def46cd2fe3a25e35fa4013e.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e27c5b73b15d4af441cfb767f425ce9.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cb99d0fc5159b5f0d3090af5033cb09.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38ed3bd10ec7d31ef2e4a3a1b7f40070.webp",980,1385]